By Connor Hart

Shares of Sagimet Biosciences rose after the company disclosed what it called positive results from a recent clinical trial of its treatment for moderate-to-severe acne.

The stock jumped 42%, to $5.20, in pre-market trading Wednesday. Through Tuesday's close, shares have lost more than one-fifth of their value in the past year.

The biopharmaceutical company before the bell said that its acne treatment, denifanstat, met all primary and secondary endpoints in a Phase 3 clinical trial in China.

Denifanstat was generally well-tolerated by patients during the trial, with incidence rates of treatment-emergent adverse events comparable between the treatment and placebo, the company said.

Chief Executive David Happel called the trial results highly encouraging, noting that the treatment represents a potentially novel approach to treat acne, one of the most prevalent skin diseases that physicians address annually.

Sagimet additionally said it recently initiated a Phase 1 first-in-human clinical trial for a separate therapy, TVB-3567, which is planned to be developed to treat acne in the U.S.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

June 04, 2025 06:44 ET (10:44 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.